Kienstra Matthew A, Neel H Bryan, Strome Scott E, Roche Patrick
Department of Otorhinolaryngology, University of South Florida, MCC-HN PROG, 12902 Magnolia Drive, Tampa, Florida, 33612-9497, USA.
Head Neck. 2003 Jun;25(6):457-63. doi: 10.1002/hed.10223.
Certain tumor antigens have been identified that stimulate an immune response, thus making them targets for immunotherapy. NY-ESO-1, MAGE-1, and MAGE-3 are such antigens. This study was undertaken to determine their presence or absence in head and neck squamous cell cancers and to correlate this with patient characteristics.
Reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry (IH) were used to identify NY-ESO-1, MAGE-1, and MAGE-3 in surgical specimens. Patient data (previous treatment, gender, age, primary site, metastasis, tumor grade, tumor stage, smoking history, and alcohol history) were collected by chart review and examined for correlation with presence or absence of antigen.
Three tumors were found to be positive for NY-ESO-1 by RT-PCR. All of these tumors were also positive for MAGE-1 and MAGE-3. IH was only positive for NY-ESO-1 in one patient. Eighteen of the 45 tumors (40%) were positive for MAGE-1 by RT-PCR. By IH, only six tumors were positive for MAGE-1. Five (83.3%) of those that were positive by IH were positive by RT-PCR. Twenty of the 45 tumors (44.4%) were positive for MAGE-3 by RT-PCR. By IH, 12 tumors were positive for MAGE-3. Nine (75%) of those positive by IH were also positive by RT-PCR. Overall, of the 45 tumors, 27 (60%) were positive by RT-PCR for at least one of the antigens. None of the patient characteristics correlated with the presence or absence of antigen.
There is high expression of MAGE-1 and MAGE-3 antigens in head and neck squamous cell carcinomas, whereas NY-ESO-1 is not significantly expressed. IH correlates but is not as sensitive as RT-PCR for detection of these antigens. There is no correlation between antigen expression and patient data. On the basis of the high levels of MAGE-1 and MAGE-3 expression, use of these antigens may serve as a potential approach to immunotherapy for squamous cell carcinoma from head and neck sources.
已鉴定出某些可刺激免疫反应的肿瘤抗原,因此使其成为免疫治疗的靶点。NY-ESO-1、MAGE-1和MAGE-3就是这类抗原。本研究旨在确定它们在头颈部鳞状细胞癌中是否存在,并将其与患者特征相关联。
采用逆转录聚合酶链反应(RT-PCR)和免疫组织化学(IH)方法在手术标本中鉴定NY-ESO-1、MAGE-1和MAGE-3。通过查阅病历收集患者数据(既往治疗、性别、年龄、原发部位、转移情况、肿瘤分级、肿瘤分期、吸烟史和饮酒史),并检查其与抗原存在与否的相关性。
通过RT-PCR发现3例肿瘤NY-ESO-1呈阳性。所有这些肿瘤MAGE-1和MAGE-3也呈阳性。免疫组织化学仅在1例患者中NY-ESO-1呈阳性。45例肿瘤中有18例(40%)通过RT-PCR检测MAGE-1呈阳性。通过免疫组织化学检测,仅6例肿瘤MAGE-1呈阳性。免疫组织化学呈阳性的病例中有5例(83.3%)RT-PCR也呈阳性。45例肿瘤中有20例(44.4%)通过RT-PCR检测MAGE-3呈阳性。通过免疫组织化学检测,12例肿瘤MAGE-3呈阳性。免疫组织化学呈阳性的病例中有9例(75%)RT-PCR也呈阳性。总体而言,45例肿瘤中有27例(60%)通过RT-PCR检测至少有一种抗原呈阳性。患者的任何特征均与抗原的存在与否无关。
头颈部鳞状细胞癌中MAGE-1和MAGE-3抗原表达较高,而NY-ESO-1表达不显著。免疫组织化学检测与RT-PCR相关,但检测这些抗原时不如RT-PCR敏感。抗原表达与患者数据之间无相关性。基于MAGE-1和MAGE-3的高表达水平,使用这些抗原可能是头颈部来源鳞状细胞癌免疫治疗的一种潜在方法。